MATcelerate HEALTH is a Royce facilitated initiative designed to accelerate the commercialisation of advanced materials technologies within the healthcare sector.

It functions as an industry-driven accelerator, connecting leading research universities with global companies to help bridge the gap between academic innovation and market-ready solutions.

Based on the same model as the Royce facilitated MATcelerate ZERO accelerator, MATcelerate HEALTH is a partnership between world leading materials research universities and leading, global MedTech companies and investors, to develop a pipeline of commercial opportunities to revolutionise healthcare.

MATcelerate HEALTH is committed to improving patient outcomes through advanced, smart medical devices, while addressing the environmental impact of medical waste, reducing healthcare costs and maximising delivery efficiency.

By leveraging Royce’s cutting-edge capabilities, along with industry and investor networks, MATcelerate HEALTH aims to transform technologies emerging from universities and hospital settings into viable, investable solutions. This will be achieved through close collaboration with leading UK universities and several of the country’s largest NHS Trusts.

Major translation bottlenecks including complex interdependencies, component integration, scalability and manufacturing and regulatory hurdles increase the risk profile of medical materials innovation and stifle commercialisation pathways.

MATcelerate HEALTH IS

• Generating high-quality opportunities for industry and commercial investors.
• Boosting innovation and adoption, turning innovative ideas into tangible benefits for patients and healthcare professionals.
• Stimulating a collaborative innovation ecosystem linking materials research expertise, systems engineering and manufacturing with the MedTech industry.

It is focused on key healthcare applications with high impact including wound care, bone implants and bioelectronics and aims to develop 50 seed level, capital investable propositions in the next 5 years.

Inspired by proven models like BioDesign, the MATcelerate HEALTH model follows a two stage approach:

Identify:

In close collaboration with the Technology Transfer Offices of our University partners, we identify high impact, investable technologies with strong commercial potential. This selection is guided by insights from clinicians, industry and investors and is supported by rigorous assessment and prioritisation

Derisk:

At the centre of MATcelerate HEALTH’s model is a commitment to derisking early-stage technologies. We provide target funding, technical infrastructure, and expert guidance in technology translation. This expert focus includes navigating commercialisation and scale-up barriers to accelerate successful proof of concept projects.

MATcelerate HEALTH offers a unique opportunity to foster innovation, access cutting-edge research, improve health care outcomes and drive long-term growth.

It provides the platform to be at forefront of technological advancements emerging from academic institutions with world-class research capabilities. Partnering with us means being part of an exciting approach to shape the future of healthcare through collaboration with some of the brightest minds in academia.

The programme:

• Increases the volume and quality of advanced materials investment opportunities for university translational and spin-out funds, along with private/corporate investors
• Increases the effectiveness of participating Technology Transfer Offices (TTOs) and industry partners licensing teams
• Provides industry with access to breakthrough materials technologies for healthcare
• Encourages university researchers to translate research in high-priority areas by providing them with a highly effective way to engage industry
• Accelerates the real-world application of materials discovery and manufacture through commercialisation at pace